File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum syndecan-1, hyaluronan and thrombomodulin levels in patients with lupus nephritis

TitleSerum syndecan-1, hyaluronan and thrombomodulin levels in patients with lupus nephritis
Authors
KeywordsLN
syndecan-1
hyaluronan
thrombomodulin
Issue Date2021
PublisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/
Citation
Rheumatology, 2021, v. 60 n. 2, p. 737-750 How to Cite?
AbstractObjectives: We investigated circulating syndecan-1, HA and thrombomodulin levels in patients with biopsy-proven Class III/IV ± V LN and their clinico-pathological associations. Patients with non-renal SLE or non-lupus chronic kidney disease, and healthy subjects served as controls. Methods: Serum syndecan-1, HA and thrombomodulin levels were determined by ELISAs. Results: Syndecan-1, HA and thrombomodulin levels were significantly higher during active LN compared with remission (P < 0.01, for all), and correlated with the level of proteinuria, estimated glomerular filtration rate, anti-dsDNA antibodies, complement 3 and serum creatinine. Longitudinal studies showed that syndecan-1 and thrombomodulin levels increased prior to clinical renal flare by 3.6 months, while HA level increased at the time of nephritic flare, and the levels decreased in parallel with treatment response. Receiver operating characteristic curve analysis showed that syndecan-1 and thrombomodulin levels distinguished patients with active LN from healthy subjects, LN patients in remission, patients with active non-renal lupus and patients with non-lupus chronic kidney disease (receiver operating characteristic area under curve of 0.98, 0.91, 0.82 and 0.95, respectively, for syndecan-1; and area under curve of 1.00, 0.84, 0.97 and 0.79, respectively, for thrombomodulin). HA level distinguished active LN from healthy subjects, LN patients in remission and non-lupus chronic kidney disease (receiver operating characteristic area under curve of 0.82, 0.71 and 0.90, respectively) but did not distinguish between renal vs non-renal lupus. Syndecan-1 and thrombomodulin levels correlated with the severity of interstitial inflammation, while HA level correlated with chronicity grading in kidney biopsies of active LN. Conclusion: Our findings suggest potential utility of serum syndecan-1, thrombomodulin and HA levels in clinical management, and their potential contribution to LN pathogenesis.
Persistent Identifierhttp://hdl.handle.net/10722/288116
ISSN
2021 Impact Factor: 7.046
2020 SCImago Journal Rankings: 1.957
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYu, KYC-
dc.contributor.authorYung, SY-
dc.contributor.authorChau, MKM-
dc.contributor.authorTang, CSO-
dc.contributor.authorYap, DYH-
dc.contributor.authorTang, AHN-
dc.contributor.authorYing, SKY-
dc.contributor.authorLee, CK-
dc.contributor.authorChan, TM-
dc.date.accessioned2020-10-05T12:08:06Z-
dc.date.available2020-10-05T12:08:06Z-
dc.date.issued2021-
dc.identifier.citationRheumatology, 2021, v. 60 n. 2, p. 737-750-
dc.identifier.issn1462-0324-
dc.identifier.urihttp://hdl.handle.net/10722/288116-
dc.description.abstractObjectives: We investigated circulating syndecan-1, HA and thrombomodulin levels in patients with biopsy-proven Class III/IV ± V LN and their clinico-pathological associations. Patients with non-renal SLE or non-lupus chronic kidney disease, and healthy subjects served as controls. Methods: Serum syndecan-1, HA and thrombomodulin levels were determined by ELISAs. Results: Syndecan-1, HA and thrombomodulin levels were significantly higher during active LN compared with remission (P < 0.01, for all), and correlated with the level of proteinuria, estimated glomerular filtration rate, anti-dsDNA antibodies, complement 3 and serum creatinine. Longitudinal studies showed that syndecan-1 and thrombomodulin levels increased prior to clinical renal flare by 3.6 months, while HA level increased at the time of nephritic flare, and the levels decreased in parallel with treatment response. Receiver operating characteristic curve analysis showed that syndecan-1 and thrombomodulin levels distinguished patients with active LN from healthy subjects, LN patients in remission, patients with active non-renal lupus and patients with non-lupus chronic kidney disease (receiver operating characteristic area under curve of 0.98, 0.91, 0.82 and 0.95, respectively, for syndecan-1; and area under curve of 1.00, 0.84, 0.97 and 0.79, respectively, for thrombomodulin). HA level distinguished active LN from healthy subjects, LN patients in remission and non-lupus chronic kidney disease (receiver operating characteristic area under curve of 0.82, 0.71 and 0.90, respectively) but did not distinguish between renal vs non-renal lupus. Syndecan-1 and thrombomodulin levels correlated with the severity of interstitial inflammation, while HA level correlated with chronicity grading in kidney biopsies of active LN. Conclusion: Our findings suggest potential utility of serum syndecan-1, thrombomodulin and HA levels in clinical management, and their potential contribution to LN pathogenesis.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/-
dc.relation.ispartofRheumatology-
dc.rightsPre-print: Journal Title] ©: [year] [owner as specified on the article] Published by Oxford University Press [on behalf of xxxxxx]. All rights reserved. Pre-print (Once an article is published, preprint notice should be amended to): This is an electronic version of an article published in [include the complete citation information for the final version of the Article as published in the print edition of the Journal.] Post-print: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in [insert journal title] following peer review. The definitive publisher-authenticated version [insert complete citation information here] is available online at: xxxxxxx [insert URL that the author will receive upon publication here].-
dc.subjectLN-
dc.subjectsyndecan-1-
dc.subjecthyaluronan-
dc.subjectthrombomodulin-
dc.titleSerum syndecan-1, hyaluronan and thrombomodulin levels in patients with lupus nephritis-
dc.typeArticle-
dc.identifier.emailYung, SY: ssyyung@hku.hk-
dc.identifier.emailTang, CSO: csotang@hkucc.hku.hk-
dc.identifier.emailYap, DYH: desmondy@hku.hk-
dc.identifier.emailTang, AHN: alextang@pathology.hku.hk-
dc.identifier.emailChan, TM: dtmchan@hkucc.hku.hk-
dc.identifier.authorityYung, SY=rp00455-
dc.identifier.authorityYap, DYH=rp01607-
dc.identifier.authorityTang, AHN=rp02468-
dc.identifier.authorityChan, TM=rp00394-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/rheumatology/keaa370-
dc.identifier.pmid32793966-
dc.identifier.scopuseid_2-s2.0-85102212433-
dc.identifier.hkuros315292-
dc.identifier.volume60-
dc.identifier.issue2-
dc.identifier.spage737-
dc.identifier.epage750-
dc.identifier.eissn1462-0332-
dc.identifier.isiWOS:000637045200047-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1462-0324-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats